However, BPC-157 promotes gut healing and repair, while GLP-1 agonists slow gut motility to aid in satiety and blood sugar control
No human safety data : The complete absence of human clinical trials means the safety profile, side effects, optimal dosing, and pharmacokinetics in humans are entirely unknown Animal-to-human translation is uncertain : Metabolic differences between mice and humans mean that the magnitude of effects (e.g., weight loss, grip strength improvement) may not translate
The mechanism is thought to involve FAK (focal adhesion kinase) and paxillin signaling, but the specific binding target for BPC 157 on a cell surface receptor has not been definitively identified and published as of 2026
[DOI] [PMC free article] [PubMed] [Google Scholar] Fernndez M
These symptoms may appear gradually and should not be ignored, especially when they persist or worsen over time
10.3390/pathogens10010015 37 GrgovS.TasiT.Radovanovi-DiniB.Benedeto-StojanovD